Brickell Biotech, a US–based developer of drug therapies for the treatment of skin diseases, has raised $7m in its series B round led by South Korea-based cosmetics maker AmorePacific’s corporate venturing unit. Alongside AmorePacific Ventures in the B round was venture capital firm Palisade Capital Management’s Concentrated Equity Partnership II fund. In July 2010, Brickell…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
